San Diego Biotech Companies: A Comprehensive Industry Guide

San Diego is one of the world’s premier biotechnology hubs, consistently ranked behind only Boston and the San Francisco Bay Area in biotech industry concentration (^[1]) (^[2]). The region’s biotech sector has matured over four decades, anchored by leading research institutions (e.g. UC San Diego, Scripps Research, Sanford Burnham Prebys, the Salk Institute) and early entrepreneurial successes (e.g. Hybritech, founded in 1978 and acquired by Eli Lilly in 1986 UC San Diego) (^[3]) (^[1]). Today the broader life sciences industry (pharma, biotech, diagnostics, medtech) supports over 75,000 jobs in San Diego County (^[4]) and has an annual regional economic output on the order of $50–56 billion (^[5]) (^[6]). Average compensation in life sciences is roughly $120–150K (^[5]) (^[7]), reflecting the high-skill, high-value nature of the work. These are individual annual-wage measures and are not directly comparable with the city’s median household-income measure. San Diego also draws major venture capital and research funding: it was the 3rd-largest U.S. region by biotech venture investment (nearly $3.8B raised in 2024 (^[8]), rising to $4.8B across 180+ deals in 2025 (^[9])), and maintains substantial NIH grant activity—though federal research funding faces significant uncertainty under the current administration (see below).

Notable biotech enterprises headquartered or operating in San Diego include leading genomics and diagnostics firms (e.g. Illumina), major drug discovery and development companies (e.g. Neurocrine Biosciences, Maravai LifeSciences, Halozyme Therapeutics, and Sorrento Therapeutics), and a vibrant startup community spanning mRNA therapies, gene and cell therapies, synthetic biology, biologics manufacturing, and bioinformatics. Case studies illustrate the breadth of the cluster: Illumina (genomic sequencing) grew into a multi-billion-dollar company out of La Jolla; Neurocrine (neurological and endocrine drugs) completed its $2.9 billion acquisition of Soleno Therapeutics on May 18, 2026, expanding its rare-disease portfolio (^[10]); TriLink/Maravai (mRNA reagents) expanded to meet COVID-19 vaccine needs; Halozyme (drug delivery) developed globally partnered biologic platforms, reaching record $1.4B revenue in 2025 (^[11]); among others.

Over 1000 local companies (2,153 life science establishments in 2023 (^[12])) work in this space, from small therapeutics startups to global corporations (including facilities of global pharma, biotech, and diagnostics firms). Table 1 lists key cluster metrics, and Table 2 summarizes representative companies across major subsectors.

While the industry endured a recent downturn in hiring and funding (2022–2024), reflecting broader biotech market corrections (^[4]) (^[13]), San Diego’s ecosystem remains robust. The region’s strengths – deep R&D talent base, specialized infrastructure, strong networks and support institutions (Biocom California, SDBN, CONNECT, etc.), and a track record of innovation – are widely cited as positioning it for a strong rebound (^[8]) (^[12]). National rankings continue to place San Diego among the top U.S. biopharma clusters (^[14]) (^[8]).

This report provides a comprehensive review of biotech in the San Diego region. It covers historical evolution, cluster drivers, major sectors and companies, quantitative economic data, case studies of leading organizations, and outlooks for future development. It draws on cited industry reports, company materials, government sources, and reporting. The goal is to present a useful reference on the San Diego biotech landscape for policymakers, investors, academics, and industry stakeholders.

Key Findings: San Diego’s biotech cluster is large and diverse (61,866 direct life-science jobs and $55.2 billion in economic output in 2025) (^[15]), led by advanced fields such as genomics, cell/gene therapy, RNA therapeutics, and immunotherapy. Institutional factors (major universities, research centers) and pro-industry policies have fostered growth (^[1]) (^[5]). After a 2022–2024 macroeconomic downturn, venture capital rebounded strongly in 2025 ($4.8B raised), though federal NIH funding cuts and policy uncertainty under the current administration pose significant new headwinds (^[16]) (^[17]). San Diego companies continue to innovate globally and attract major deals: Roche completed its acquisition of Poseida Therapeutics in January 2025 for approximately $1.0 billion in upfront equity value, plus contingent-value rights that could bring the total to $1.5 billion (^[18]), and Neurocrine completed its $2.9 billion acquisition of Soleno Therapeutics in May 2026 (^[10]) (^[9]). Strategic challenges going forward include sustaining talent pipelines (competing with Silicon Valley and Boston), navigating federal research funding uncertainty, and expanding local manufacturing. These issues are explored further in the report’s analysis sections.

The term “biotechnology” encompasses a broad range of industries that use biological processes or organisms to develop products in health care, agriculture, environment, and industrial applications. In Silicon Valley parlance “life sciences” is often used interchangeably when including medical devices, diagnostics, and pharmaceutical products. San Diego’s life sciences industry indeed spans pharmaceuticals, biologics, molecular diagnostics, genomics, cell and gene therapies, research tools, and related subfields. For this report, “biotech companies” refers broadly to firms in San Diego County whose primary business is life-science innovation—such as drug discovery and development, biologics, diagnostics, or genomics—setting aside companies strictly focused on traditional medical devices or non-biotech fields.

One indicator of San Diego’s position is the number of firms: in 2023, there were about 2,153 life science companies active in the region (^[12]). This cluster is ranked among the largest in the U.S. and globally. As early as 2008, San Diego has been recognized as having the third-largest concentration of biotech companies worldwide, behind the Bay Area and Greater Boston (^[1]). This enduring status is tied to the region’s sustained investment in above-average biotech infrastructure and workforce over several decades. Table 1, below, summarizes key scale metrics that highlight San Diego’s biotech cluster magnitude.

Metric	San Diego (most recent)	Source
Life Science Jobs (San Diego County)	61,866 direct jobs (2025)	Biocom 2026 EIR ([15])
Biotech/Life Science Companies (est.)	~1,400+ (2025)	Industry directories ([19])
Annual Econ. Output of Life Sciences	$55.2B (2025)	Biocom 2026 EIR ([15])
Avg. Life-Science Wage	$120,743 (2023); mfg avg $135,147 (2024)	Axios ([7]); Biocom
Total VC Funding (2025, regional biotech)	$4.8B (180+ deals)	Business of SD ([9])
NIH Funding (2024)	$1.458B (2,395 awards)	BIOCOM/NCATS data ([20])
UCSD Total Research Funding (FY2025)	$1.7B	SD Regional EDC ([21])
Patents (biotech families, 2024)	16,668	BIOCOM/JLL ([22])
Lab space (Sq Ft, 2024)	26.8M	BIOCOM/JLL ([22])

Table 1. Key economic and innovation indicators for San Diego’s life sciences/biotech cluster. Sources are cited.

In addition, San Diego continues to attract major life-science conferences and investments: for example, the 2024 BIO International Convention – the world’s largest biotech industry conference – had over 18,000 attendees in San Diego (^[23]). Global companies have announced billions in new R&D infrastructure (see Section on Real Estate and Facilities), underscoring confidence in the region.

The San Diego biotech story dates back to the 1960s and 1970s, coinciding with the growth of nearby academic institutions. UC San Diego (established 1960), Scripps Institution of Oceanography, the Salk Institute (1963), and Sanford Burnham Prebys—founded in 1976 by William and Lillian Fishman as the La Jolla Cancer Research Foundation—were among the early research hubs on Torrey Pines Mesa and in La Jolla (^[24]). According to one account, San Diego’s “original spark” came from patient planning by visionary leaders in the 1950s-60s (^[25]). These academics laid the groundwork for future biotech.

A pivotal milestone occurred in 1978, when Hybritech—an early San Diego biotech company—was founded by UCSD scientists and venture capitalists (^[26]). Hybritech’s monoclonal antibody diagnostics (notably the first FT4 test for thyroid function) became widely adopted, and in 1986 the company was sold to Eli Lilly for about $450 million (^[3]). This commercialization validated San Diego’s potential and provided capital and entrepreneurial talent for new ventures (^[3]) (^[27]).

According to contemporary accounts, Hybritech set off “a generation” of biotech startups by seeding a new entrepreneurial ecosystem (^[3]) (^[27]). Other early companies included Gen-Probe (1983, genetic diagnostics). By the late 1980s, San Diego was firmly on the biotech map. A 1990 LA Times article noted that the region’s “formal first successes” in drug discovery and company creation date from this era (^[1]).

Throughout the 1990s, the cluster diversified. Illumina (founded 1998) built on local genomics expertise to become a global leader in DNA sequencing tools; Ligand Pharmaceuticals and Neurocrine Biosciences emerged in therapeutics; Scripps Research expanded its translational programs. By 2007, San Diego’s life science economy already employed ~44,000 people across ~700 companies (^[27]) (including medical devices), and was generating roughly $9 billion in annual impact (^[27]). (These figures have since roughly doubled, reflecting continued growth into the late 2010s.)

From the start, public and private institutions in San Diego collaborated to nurture biotech. Leadership included early advocates like UCSD chancellor Richard Atkinson, Salk co-founder Jonas Salk, local philanthropists, and business leaders. Local government also committed resources: for instance, San Diego provided Torrey Pines Mesa land for campus development, helping establish what is now a major biotechnology district in north La Jolla (^[28]). Biotech trade associations (later Biocom) formed in the 1990s to support the industry. Throughout, San Diego maintained a balance of academic R&D and commercialization: strong university science fed local startups and attracted industry R&D labs.

By the early 2000s, San Diego’s growth accelerated. Investments poured in: venture capital (VC) for SoCal life sciences climbed to over $1.6 billion by 2007 (^[27]). Pharmaceutical and biotech companies (both domestic and international) set up R&D and manufacturing sites in the region. For example, large firms such as Genentech (later Roche following Genentech’s acquisition) and Pfizer/Schering-Plough established sizable campuses. (Later, Pfizer sold its Torrey Pines R&D campus to BioMed Realty in 2024 (^[29]).) The late 1990s and 2000s also saw expansion in areas like stem cells (with researchers from UCSD, Sanford Burnham pre-Bios), immunology, and molecular diagnostics.

The global biotech boom of the 2010s found San Diego well positioned. Advances in genomics, synthetic biology, and personalized medicine – fields in which UCSD, J. Craig Venter Institute, and others were active – aligned with industry trends. Young companies in cell therapy, including Fate Therapeutics, emerged from the region’s research ecosystem. Meanwhile, the region’s life-sciences workforce and output continued to grow: by 2015, San Diego County supported over 50,000 life-sciences jobs and contributed ~$40B in economic output (benchmarks approximated between the earlier Biocom report (^[5]) and later Axios report (^[30])).

During this period, certain specializations emerged. San Diego became known as a leader in genomics and sequencing (anchored by Illumina and local DNA sequencing startups), RNA biology and RNA therapeutics, cell and gene therapy, and translational immunology. The cluster also attracted biotechnology-tools, research-services, and manufacturing activity.

Academic entrepreneurship played a constant role: technology transfer offices at UCSD and other institutions aided spinouts (such as Santa Cruz’s Idunn Technologies) (^[27]). The region’s success stories in rare disease therapeutics and proprietary diagnostics raised San Diego’s global profile.

By 2019–2020, right before the COVID-19 pandemic, San Diego was firmly established as one of America’s top three life-sciences clusters in many rankings (^[1]) (^[14]). For example, San Diego County was home to dozens of biotech firms employing over 50,000 people, with total cluster output around $54–$56B per year (^[31]) (^[6]). The industry had a commanding presence in the local economy alongside defense and tourism.

Research Institutions and Talent Pipeline

A core strength of San Diego’s biotech cluster is its unique concentration of research universities and institutes. UC San Diego (UCSD) is among the nation’s leading life-science research universities, consistently ranking top 10 in NIH funding. Its medical and bioengineering faculties are prolific in biotechnology and biomedical research. The campus, along with the adjacent UCSD Medical Center, is a major employer and a source of spinouts (e.g. ZS Pharma, Fate Therapeutics, Avidity Biosciences). Over 7,000 graduate students enroll at UCSD, many in STEM fields, feeding into local biotech jobs.

Scripps Research Institute (with facilities in La Jolla and Jupiter, Florida) is a global leader in biomedical science, particularly small-molecule therapeutics, immunology, and biochemistry. Scripps has helped generate biotechnology companies and collaborations. Sanford Burnham Prebys in La Jolla and the Salk Institute for Biological Studies in nearby La Jolla also contribute basic bioscience and biotechnology innovation. Multiple research hospitals, including UC San Diego Health, Rady Children’s, Sharp HealthCare, and Scripps Health, support clinical trials and translational research.

Beyond universities, the J. Craig Venter Institute (JCVI) has been a landmark in genomics. The downtown Research and Development District (RaDD) has attracted JCVI’s move (^[32]). Biomedical research in San Diego draws on academic labs, imaging centers, and specialized core facilities. Life-science incubators and accelerators, including Qualcomm Institute, CONNECT, JLABS, and LabFellows, further support pre-commercial ventures.

Collectively, these institutions produce a deep talent pool. At UC San Diego alone, 720 Ph.D.s and 13,211 total degrees were conferred in 2024–25 (^[33]). This workforce supply is a key draw: “there’s a vast talent pool in San Diego… these kinds of companies aren’t built around one person. It takes a team of people, and San Diego provides that kind of talent,” noted J&J’s former Adolphus Busch Chair Dr. Richard Scheller (^[34]). Industry leaders argue that the region’s education / research capacity is unmatched (“San Diego is a hotbed of talent, an asset that can’t easily be replicated elsewhere” (^[35])).

However, a significant challenge is talent retention and attraction. San Diego’s cost of living and housing pressures have begun to make recruiting difficult. Recent reports note that compensation in San Diego counts against a high cost of living, causing the region to rank only mid-range (7th out of 10 peer metros) in wage competitiveness (^[36]). Competition from Silicon Valley, Boston, and emerging hubs can pull talent away for higher pay or more startups per capita. Industry stakeholders emphasize that sustaining the specialized workforce (scientists, engineers, technicians) is critical for growth.

Education-to-industry pipelines, including specialized biotech training programs, are therefore seen as priorities. For instance, UCSD Extension and local community colleges offer biotech training certifications, and partnerships (e.g. with Illumina) provide internships. There are also local proposals to enhance STEM career pipelines in K–12. Biocom California and others advocate for workforce development to meet biotech demands (especially as the region builds out new lab capacity).

San Diego’s biotech companies cluster in a few key geographies with supporting infrastructure:

• La Jolla / Torrey Pines Mesa: Centered on UCSD, Scripps, Salk, Sanford-Burnham, this area has both academic and small-company presence. It houses older lab real estate (Torrey Pines Science Park) and new developments (e.g. the Torrey Pines Science Center complex). Many early biotech startups and research spinouts are based here.
• Sorrento Mesa / Sorrento Valley: This inland area (north of I-8) in the Miramar tech corridor has become a life-sciences park. Major campuses of biotech, pharma and biotech service companies are located here. Notable occupants include Halozyme, Maravai LifeSciences, and several venture-backed startups. With recent projects like IQHQ’s 690K sqft Pacific Center (opened 2025) (^[37]) and Sterling Bay’s Sorrento Gateway, the Sorrento Valley submarket is rapidly growing.
• UTC / University Towne Centre: North of La Jolla, near UCSD and Torrey Pines, this CBD-fringe district is being developed by Alexandria Real Estate. A recent landmark is Alexandria’s record 466,598-sq-ft anchor lease in 2023 for an undisclosed global pharma tenant (^[38]) at Campus Point. This “Megacampus” (Alexandria’s Pacific Grove, combining multiple projects) signals major new lab space coming online.
• Downtown San Diego: Traditionally light on labs, Downtown is emerging as a biotech center. The new IQHQ Research and Development District (RaDD), a $1.6B, 1.7M sqft complex, broke ground near the bay. In 2024-2025, major tenants including the J. Craig Venter Institute announced relocation to RaDD (^[32]). Downtown’s redevelopment (linked to the upcoming UCSD campus expansion) is intended to anchor more life science R&D in the urban core.
• Carlsbad / North County: Suburban north San Diego hosts life-science manufacturing, research, and testing activity. It includes Maravai LifeSciences and other life-science businesses, alongside a broader base of technology and manufacturing employers.

Overall, San Diego County contains over 26 million square feet of wet lab space (4th most nationally) (^[39]), a key resource. Notably, local vacancy rates have remained relatively low historically, indicating steady demand. However, a surge of new development is underway: projects under construction could increase lab inventory by millions of square feet in the next few years. (San Diego had a 16.7% life-science vacancy rate in mid-2024, largely due to new construction coming online (^[40]).)

Industrial support industries include contract research and manufacturing organizations, specialized equipment suppliers, and business-service providers. The region’s defense, aerospace, and military presence can also create opportunities for collaboration in areas such as biodefense and public-health preparedness.

A defining feature of San Diego’s biotech hub is its ability to attract investment. Venture capital has fueled many startups and expansions. As of mid-2020s, San Diego was routinely in the top 3 biopharma markets by VC funding (^[8]) (behind only Boston and the Bay Area). For example, Sunset Park Ventures and other local VC firms have led large rounds here. According to BIOCOM/Hsbc data, the region raised roughly $3.8 billion in 2024 for biotech ventures (^[8]) – even as investment levels dipped from the 2021 COVID-boom peak (around $5B in 2021 to $2.1B in 2023 (^[13])).

Table 1 above reflects this: GEN ranks San Diego as third in VC behind Boston/SF (^[8]). The funding rebound continued into 2025: the region raised $4.8B across 180+ biotech deals, with life sciences taking 55% of San Diego's total $7.3B venture haul (^[9]). Several high-profile financing rounds illustrate the dynamic: Crystalys Therapeutics emerged from stealth with a $205M Series A in September 2025; Erasca raised a $200M Series C for precision oncology (led by Alexandria Venture Investments); and Outpace Bio closed a $128M Series B for rare disease gene therapy (^[9]). Average seed rounds in San Diego now run about $8M and Series A about $35M—lower than Boston but competitive nationally (^[19]).

Public markets also support the region: dozens of life-science companies founded in San Diego are publicly traded on NASDAQ (e.g. Illumina, Neurocrine, Halozyme, Acadia Pharmaceuticals, etc.), with aggregate market cap in the tens of billions. Acquisitions have delivered significant capital: Johnson & Johnson’s $2.1B purchase of Ambrx (a San Diego protein-engineering company) in 2024 (^[6]); Novartis announced its approximately $12 billion agreement to acquire Avidity Biosciences in October 2025 and completed the acquisition on February 27, 2026; and Roche completed its Poseida Therapeutics acquisition in 2025. These transactions reflect sustained global interest in San Diego innovation. In total, San Diego biotech M&A activity exceeded $15B in 2024 alone (^[41]).

Biocom California’s annual economic impact reports (with Deloitte) and life science associations regularly publish funding analyses. A Sept 2024 analysis by Glint Lab noted that San Diego’s biotech funding spiked during COVID (2020–21) then “returned to pre-COVID levels” by 2024 (^[42]). These fluctuations mirror national trends, but local venture capitalists and corporate R&D budgets remain a backbone of the financing structure.

Government funding is also significant—but faces unprecedented uncertainty. San Diego area institutions historically earned >$1.4B/year in NIH grants (San Diego was ~10th nationally, with $1.458B in 2024 (^[20])). UC San Diego secured $1.7B in total research funding in fiscal year 2025 from federal, state, industry, and philanthropic sources (^[21]). Department of Defense and VA grants for bio-defense research are also non-negligible (given the nearby Camp Pendleton and San Diego Naval base). National programs (like the California Institute for Regenerative Medicine – CIRM) direct state funds to UCSD and private startups locally.

Federal research policy remains an important source of uncertainty. In February 2025, NIH issued guidance establishing a 15% indirect-cost rate for affected awards. A federal district court permanently enjoined and vacated that policy on April 4, 2025; the cap therefore is not an operative NIH funding rule. This report does not project a UC San Diego loss from the enjoined policy (^[43]; AAU summary of the court judgment).

One observation: access to capital affects composition. The San Diego ecosystem has a strong venture arm which encourages early-stage startup activity. While VC funding rebounded in 2025, uncertainty around federal research funding could weaken the academic-to-startup pipeline that has historically fed local biotech innovation. Some firms have relocated to more liquid markets or deferred expansion. The five-year R&D amortization rule continues to disincentivize small biotech R&D spending (^[44]). Overall, while private capital flows are recovering, all stakeholders acknowledge that the San Diego biotech industry faces a new and potentially structural threat from federal research funding cuts.

San Diego’s biotech ecosystem is reinforced by numerous support organizations and networks. Biocom California (Southern California region headquartered in San Diego) is a chief trade association. It advocates for industry-friendly policy (e.g. tax credits, zoning), organizes networking events (Biocom CEO Summit, BIO conference receptions), and provides market data (economic reports cited throughout this report). San Diego Biotechnology Network (SDBN) is a volunteer-run nonprofit providing a catalog of resources and weekly news. CONNECT is a UC San Diego-founded, mission-driven 501(c)(3) nonprofit that supports entrepreneurs through mentoring, education, and investor connections (^[45]). Incubators such as Biolabs San Diego, JLABS @San Diego (Johnson & Johnson), and Cubic provide office/lab space for startups. Venture forums like Biotech Showcase often have San Diego contingents.

State-level programs help too: California’s Go-Bio tax credit and Blueprint for Business regulatory assistance have provided incentives, although these benefit the whole state. Locally, the city and county governments have adopted plans to ensure sufficient R&D-zoned land (e.g. adding research parks, Mira Mesa expansion) (^[46]). SANDAG and EDD (Employment Development Dept) track cluster data and occasionally offer workforce development grants.

In summary, the intertwined network of universities, companies, investors, government bodies and nonprofits constitutes a robust cluster ecosystem. This communal approach (“cluster density”) is often cited as a key factor: companies can easily recruit experienced professionals from peers, academic collaborations are commonplace (e.g. J&J co-publishing with UCSD teams), and shared resources (like the San Diego IRB (Institutional Review Board)) lower barriers for clinical research.

Economic Impact and Workforce

As shown in Table 1, life sciences is a leading economic engine for San Diego. Biocom’s 2022 report estimated the life science sector (biotech + pharmaceuticals + medical device + research institutions) supported ~71,000 direct jobs in the county (with average annual wage $149,528) (^[5]). Updated figures for 2023 put jobs at ~75,816 (^[4]), with average pay around $120,743 (^[7]) (note the discrepancy: Biocom described life sciences wages $149K average in 2021 (^[5]), whereas Axios indicates $120K – possibly a difference in measurement or timeframe). These figures describe individual annual wages, whereas $99K is San Diego’s median household income (^[7])); they should not be treated as directly comparable measures.

The life-sciences employment growth trajectory has not been smooth. After nearly a decade of steady rises, 2022–2024 saw a slight contraction. According to BioSpace, San Diego life science jobs dipped 2.5% in 2023 to 75,816 (^[4]). Biocom similarly reported a small decline, with 2023 output around $56.6B (compared to prior ~$54B–$56B) (^[6]). The California Life Sciences “San Diego Snapshot” noted the number of establishments went from 2,215 in 2022 to 2,153 in early 2023 (^[12]). Analyses attribute this to an industry-wide funding crunch: After a COVID-era VC boom ($5B in 2021), investment fell around 40% in 2022 (to $2.5B) and further in 2023 (to $2.1B) (^[13]). Startups cut R&D and headcount in response. Even large companies (e.g. Thermo Fisher, Takeda) reduced local staff (^[47]) as they optimized operations globally.

Despite that recent dip, the overall trend is strongly upward over a 5–10 year span. San Diego’s life science GDP and workforce have grown by double digits since the early 2010s, far faster than general industry. Axios notes the cluster is still >10% larger than five years prior (^[48]). The 2024 Biocom report confirmed that healthcare & biotech saw the fastest job gains in 2021 (Biocom’s most recent annual data series), with biotechnology roles up 18% (^[5]). Moreover, the San Diego region consistently ranks in the top 10 nationally for life sciences jobs per capita and cluster specialization (^[49]).

In short, San Diego’s biotech sector is mature but still expanding, even if the growth rate has moderated. The sector’s footprint (71–76K jobs, >$50B output) dwarfs most other local industries. Also, it is a major employer of PhD-level scientists and engineers, directly underpinning economic development. As Biocom’s VP Miguel Motta remarked in mid-2024, the existing talent base is “the backbone” of the ecosystem and should support long-term growth (^[50]).

San Diego’s biotech companies span multiple subsectors. A broad classification gives:

• Therapeutics (Pharmaceutical / Biotech): Companies developing prescription medicines—small molecules, biologics, and cell or gene therapies—for diseases. Representative companies include Neurocrine Biosciences (CNS/endocrine drugs; it completed its $2.9 billion acquisition of Soleno Therapeutics in May 2026), Acadia Pharmaceuticals (neurology drugs), Krystal Biotech (gene therapy), Fate Therapeutics (cell therapies), and Sorrento Therapeutics (which filed Chapter 11 bankruptcy in February 2023 (^[51])).

• Diagnostics and Genomics: This segment includes molecular diagnostics, genomic testing, biomarkers, sequencing systems, sample-preparation technologies, and related software. Illumina is the region’s best-known genomics company and has helped establish San Diego as a major center for next-generation sequencing. The regional ecosystem also includes smaller diagnostics, genomics, and research-tool businesses.

• Bioprocessing / CDMO: Manufacturing of biologics and related materials. San Diego has contract development, manufacturing, and bioprocessing activity, alongside CMO spinoffs. Emerging gene therapy CDMOs (NuBioGene, etc.) exist. In 2025, Alexandria Real Estate announced a 466K-sqft lab for an undisclosed pharma (^[38]), reflecting demand for production and scale-up space.

• Biotech Tools and R&D Services: Companies providing research reagents, software, or tools. Examples: Maravai LifeSciences (reagents for genomics & cell therapy), TriLink BioTechnologies (mRNA synthesis, now part of Maravai (^[52])), Inscripta (instrumentation for genome editing), Angiocrine (synthetic growth factors), Organovo (3D bio-printing tissues). Prolific (labware), CARY (lab logistics). The presence of tech co’s like Illumina stimulates an ecosystem of supporting manufacturers and service providers.

• Agriculture and Environmental Biotech (smaller presence): Some local startups (e.g. Evolva, Pivot Bio – though headquartered elsewhere) historically had ties to SD universities. Pure protein startups (Impossible Foods, but mainly in NorCal now) had research impetus here. This remains a modest segment but occasionally produces spinouts (soil bacteria research, algae biofuels at UCSD, etc.).

• Digital / Computational Biology: San Diego companies and research groups use bioinformatics, data science, and machine learning across drug discovery, genomics, and RNA research. The EDC’s RNA report notes growing software-development roles in San Diego RNA firms (^[53]). Specific company claims in this fast-changing area should be supported by current corporate sources.

The diversity of the cluster is seen in the range of products and pipelines. A 2024 analysis by SciSpot identified 20 “top biotech startups” in San Diego, half of which focus on therapeutics (oncology, autoimmune, neurology) and others in diagnostics or research tools (^[54]). Despite fluctuations, investment and innovation cut across all these domains. Many SD companies collaborate with each other regionally—for example, STEM cells therapeutics may work with local bio-makers for reagents, or a gene therapy startup may co-locate at a shared production facility.

Gender, Equity, and Diversity Issues

Although not the main focus of this report, it is worth noting current conversations. Recent state and national studies highlight underrepresentation of women and minorities in biotech leadership. Local biotech, like elsewhere, has initiated programs to improve diversity. Biocom and other organizations run mentorship programs for underrepresented entrepreneurs. The NIH’s push for diversity in research funding also flows through SD institutes. While detailed data is scarce, industry stakeholders cite diversity as a priority for inclusivity and tapping broader talent pools.

Below we highlight representative firms to illustrate key sectors of San Diego biotech.

Illumina, Inc. – Genomic Sequencing Pioneer

Illumina (founded 1998 in La Jolla) is a world leader in genome sequencing and array-based technologies. Its instruments, consumables and software serve research and clinical markets globally. Illumina’s annual revenue peaked at about $4.5B in 2021; after a challenging period that included a CEO departure, cost restructuring, and the forced divestiture of GRAIL (its cancer screening subsidiary, ordered by regulators in 2024), the company stabilized under new CEO Jacob Thaysen. Illumina reported fiscal-year 2025 revenue of $4.34B and guided fiscal-year 2026 total-company revenue of $4.5–$4.6B; Q4 2025 revenue was $1.16B, up 5% year over year (^[55]). The firm has undergone significant restructuring, cutting approximately 12% of its global workforce over the past year to improve profitability (^[56]).

Illumina’s NovaSeq X platform transition has been a major focus: by Q4 2025, roughly 80% of volumes and 55% of revenue had migrated to the new platform, with clinical consumables expected to grow double-digit to mid-teens in 2026 (^[57]). The company also acquired SomaLogic (proteomics) to diversify beyond sequencing. Illumina’s success has had “ecosystem” effects: dozens of genomics startups (e.g. Helix, Personalis, Element Biosciences) spun out of Illumina alumni or partners.

Illumina’s presence helps attract talent and investment to San Diego. Its campus expansion over the last decade added millions of sq ft of lab space here, keeping jobs local. The company partners with UCSD (joint genomics initiatives) and has been a multisector national partner. A notable corporate saga: Illumina’s acquisition of GRAIL was challenged by the FTC and EC on antitrust grounds, forcing the company to divest GRAIL in 2024—reflecting how seriously regulators view genomics market concentration. Despite recent restructuring challenges, Illumina continues to drive local innovation and remains the anchor tenant of San Diego’s genomics cluster.

Neurocrine Biosciences – Clinical Drug Development

Neurocrine Biosciences is a San Diego-founded pharmaceutical company specializing in neurological, endocrine, and psychiatric disorders. Co-founded in 1992 by UCSD neuroscientists, Neurocrine grew over three decades into a major public company (NASDAQ:NBIX). Its product INGREZZA® is FDA-approved for adults with tardive dyskinesia and chorea associated with Huntington’s disease; it is not approved to treat Parkinson’s disease (^[58]). Under CEO Kevin Gorman, Neurocrine has become one of San Diego’s most successful standalone biotechs. INGREZZA generated strong commercial growth, establishing itself as a multi-billion-dollar franchise that anchors the company’s revenue base.

In May 2026, Neurocrine completed its largest-ever M&A transaction, acquiring Soleno Therapeutics for $2.9 billion to expand into rare disease and add VYKAT XR (diazoxide choline), an FDA-approved treatment for hyperphagia in adults and pediatric patients aged four years and older with Prader-Willi syndrome (^[10]). The transaction broadened Neurocrine’s commercial portfolio in endocrinology and rare disease.

Neurocrine’s continued independence and growth are emblematic of San Diego’s pharma chops—demonstrating that a mid-cap biotech can build blockbuster drugs, execute major acquisitions, and retain a large workforce locally. The company employs hundreds at its UTC-area San Diego headquarters and remains one of the region’s most prominent biotech employers.

Halozyme Therapeutics – Biologics and Drug Delivery

Halozyme Therapeutics, Inc. (NASDAQ:HALO; public since 2004) is a San Diego biotech known for its enzyme-based drug delivery platforms. Halozyme’s proprietary ENHANZE® technology (rHuPH20 hyaluronidase) is licensed to multiple large pharma partners (including Roche, Janssen, Pfizer, and argenx). Major partnered products utilizing Halozyme’s technology include Janssen’s DARZALEX FASPRO® (subcutaneous daratumumab, with 2025 DARZALEX franchise sales of $14.3B) and argenx’s VYVGART Hytrulo® (2025 sales of $4.15B) (^[59]). Halozyme reported record full-year 2025 revenue of $1.4 billion (up 38% year-over-year), with royalty revenue surging 52% to $868M (^[11]). The company raised 2026 revenue guidance to $1.71–$1.81B and has a clear line of sight to more than $2B in total revenue by 2028.

Headquartered in San Diego, Halozyme has grown significantly as its royalty base expanded. Its presence underscores San Diego’s strength in biologic therapeutics. Halozyme also invested in portfolio expansion through M&A (acquiring Antares Pharma for injectable drug delivery in 2022) and signed new platform deals, including partnerships with Hypercon and Surf Bio that extend its ENHANZE® platform into the 2040s (^[60]). Halozyme stands as a premier example of an SD biotech successfully out-licensing transformative technology to global pharma while remaining a local R&D and commercial engine.

Maravai LifeSciences – Reagents for Biotech

Maravai LifeSciences (NASDAQ:MRVI), based in Carlsbad (north SD), provides reagents and raw materials for biotechnology manufacturing and research. Maravai was formed in March 2014 and acquired TriLink BioTechnologies in September 2016; it was not formed through a 2017 merger (^[61]). Maravai’s products (nucleic acid synthesis kits, proteins, reagents) are critical for genomics and therapeutics. In 2023, Maravai acquired molecular biology companies to expand its capabilities (^[52]). TriLink BioTechnologies, now a Maravai brand, expanded in 2024 with a new mRNA production facility in San Diego to meet demand (^[62]).

Maravai represents the cluster’s specialization in enabling technologies. Its growth was fuelled by COVID-19 vaccine ramp-up (as makers needed more GMP-grade RNA, modified bases, etc.). The company’s San Diego operations employ hundreds and collaborate with academic labs (providing materials for local research). Maravai’s success story highlights how supply-chain and platform firms in SD benefit from regional networks.

Other Notable Companies

• Mirati Therapeutics was acquired by Bristol Myers Squibb in early 2024 for up to $5.8B (including a $1B contingent value right), giving BMS the KRAS inhibitor Krazati for non-small cell lung cancer. BMS subsequently laid off over 250 workers at Mirati’s San Diego headquarters at 3545 Cray Court, with the majority of Mirati’s 400+ workforce let go over the following year (^[63]), showing how big pharma M&A can have significant local workforce impacts.
• Avidity Biosciences – a San Diego RNA therapeutics company acquired by Novartis for approximately $12B in 2025, underscoring Big Pharma’s appetite for SD-based RNA modalities targeting rare neuromuscular diseases (^[9]).
• Poseida Therapeutics – a San Diego cell-therapy and genetic-medicines company acquired by Roche in January 2025. Roche paid $9.00 per share in cash (approximately $1.0 billion in upfront equity value) plus a contingent value right worth up to $4.00 per share, for potential total consideration of up to approximately $1.5 billion (^[18]).
• Takeda R&D Center San Diego (downtown) – part of Japan’s Takeda with 300+ employees, closed in 2023 (^[64]) as the company consolidated its global R&D.
• Thermo Fisher Scientific – a global supplies/instruments giant, with major SD campuses (notably in Carlsbad, Sorrento Valley). In late 2023, part of its SD workforce (~600 jobs) was cut (^[47]), reflecting corporate reorganization.
• Stem cell and regenerative companies – e.g. Fate Therapeutics (iPSC-based off-the-shelf cell therapies), which in 2025 advanced FT819, its off-the-shelf CAR-T therapy, into expanded Phase 1 enrollment across 16 clinical sites globally and is planning a registration study in 2026 (^[65]). Cytokinetics (heart/muscle R&D) relocated HQ to SF but maintains R&D in SD.
• Diagnostics startups – e.g. Personalis (genome sequencing for cancer diagnostics), Element Biosciences (raised over $100M in 2024 for its AVITI sequencing platform). San Diego remains a site for clinical trial services and advanced genomics platforms.

This selection is partial but illustrative: biotech in San Diego ranges from genomics to drugs to tools, from early-stage startups to global enterprises. Table 2 provides a broader sampling of companies and their primary areas, compiled from industry directories (^[66]) (^[67]) and corporate sources.

Multiple cutting-edge research themes thread through the San Diego biotech scene:

• Genomics and Precision Medicine: San Diego was an early hub for genome sequencing and continues to have activity in next-generation sequencing, single-cell sequencing, bioinformatics, and multi-omics diagnostics. Illumina is the region’s best-known genomics company.

• RNA-Based Therapeutics: The dramatic success of mRNA vaccines spotlighted San Diego’s RNA expertise. Arcturus Therapeutics, which is based in San Diego, develops RNA medicines for liver and respiratory rare diseases; it developed KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine (^[68]). The San Diego RNA cluster (which EDC reports is ~$6B annually and ~11k jobs (^[69])) contributed to the COVID response and now works on RNA therapies for HIV, cancer, rare diseases. The RNA cluster is particularly noteworthy in attributions: San Diego ranks among the top U.S. “RNA hubs” and has advanced mfg capabilities for mRNA vaccines and siRNA therapies (^[69]).

• Cell and Gene Therapies: San Diego has activity in CAR-T, gene-editing, and cell-therapy research and development. Fate Therapeutics, which develops iPSC-derived cell therapies, is one local example. The proximity to genomics and research institutions supports this work.

• Immunotherapy and Biologics: Antibody drugs and immuno-engineering are active areas of research and development in the region. Ligand describes its business as royalty aggregation and licensing of technology platforms, rather than as a monoclonal-antibody developer; Decibel Therapeutics ceased to be an independent company when Regeneron completed its acquisition in September 2023 (^[70]; Regeneron). Specific local-company examples in this fast-changing area should be verified against current corporate sources.

• Microbiome and Inflammation: Microbiome and inflammation research is an active scientific area, but company examples should be included only when their current San Diego connection and corporate status can be verified from authoritative sources.

• Diagnostics & Instruments: Local engineering resources have spawned rugged point-of-care diagnostics and lab automation tools. mesa biotech companies like Cepheid (acquired by Danaher) and Genmark (acquired by Roche) have created platforms for rapid testing. Mesa’s startups like Mesa Biotech (COVID PCR tests) boomed during the pandemic. These contributions underscore the engineering culture San Diego shares.

Collaboration with Tech (AI/ML): As noted, many biotech projects incorporate data science – especially since the COVID era. San Diego has a budding biotech data-science niche, with startups using AI for drug discovery (e.g. DeepTrack Therapeutics), though not as large as in Boston or Bay Area. Still, AI partnerships exist (e.g. UCSD’s allergy genomics via AI).

All the above are supported by a culture of open collaboration. Annual events (BIO, Biocom Summits, local conferences) foster idea-sharing, even across competing firms. San Diego also benefits from its biotech+defense mix: research in biodefense (DARPA-funded) and health tech helps biotech firms think about rapid manufacturing and scale-up in pandemics.

Economic Contribution

The combined labor income and economic output of San Diego biotech is staggering. We cite Biocom and Axios figures (Table 1) showing direct output $54–$56B. Indirectly, multiplier effects on construction, services, and downstream biotech suppliers amplify the impact. For example, one EDC analysis found that every 100 biotech jobs in San Diego support an additional 150 jobs in the wider economy (service, manufacturing, trade) (^[71]). Using regional multipliers, it is estimated that life science companies indirectly support another 60,000–100,000 jobs beyond their payroll.

The wage premium in biotech is notable. Axios reported an average industry wage of $120,743 in 2023 (^[7]), and earlier Biocom data cited $149,528 (life science median in 2021) (^[5]). These are individual annual-wage measures, while $99K is the city’s median household-income measure (^[7]); the two figures are not directly comparable. The wage figures nonetheless indicate that life-sciences employment includes many highly skilled roles. Economists credit the biotech cluster with driving up the per-capita GDP of San Diego substantially above the state average.

On VC funding, GEN’s ranking highlights that San Diego (“America’s Finest City”) saw the largest lease by Alexandria and $3.8B VC in 2024 (^[38]) (^[8]). It finished 3rd in venture funding, 4th in patents, 4th in lab space nationally (^[8]). These metrics signify robust ongoing innovation. However, the cluster lagged in jobs ranking (#8 at 71k) and NIH funding (#10 at $1.458B, down 10% YOY in 2024) (^[72]). This suggests that while San Diego is still a heavyweight in R&D capacity and private investment, it faces a relative slowdown in research spending and job growth.

In absolute terms, California as a whole leads the U.S. in biotech: 1.15M jobs, $395B output (^[73]). Within California, the Bay Area, San Diego, and Los Angeles each contribute north of $50B. San Diego’s $54B output (2024) (^[31]) thus is roughly 14% of the state’s life science GDP. Comparisons show San Diego’s cluster is critical not just locally but to California and national biotech, e.g. hosting a share of national NIH grants and patents disproportionate to its population.

Recent data capture the volatility: The Biocom 2022 highlight claimed a 49.8B impact (^[5]) versus Axios’s $56.6B for 2023 (^[6]); while both are credible, this wide range might reflect differences in what’s counted or year variation. Regardless, around $50–$60B per year is typical. For perspective, San Diego’s biotech output rivals or exceeds state industries like aerospace, tourism, or agriculture.

The San Diego biotech industry mirrors global trends but with some local flavors. The 2022–2024 downturn in biotech hiring and funding was attributed to high inflation and interest rates drying up VC and raising cost of capital (^[74]); policy uncertainties over R&D tax deductions (^[44]); and stock market volatility. By 2025, venture capital rebounded significantly ($4.8B for SD biotech), but a new and potentially more structural threat emerged: federal research funding cuts. Changes and uncertainty in federal research funding could affect universities and research institutions; however, the NIH 15% indirect-cost-cap policy was permanently enjoined and vacated in April 2025 and is not in effect (^[43]; AAU summary of the court judgment). A STAT News investigation in August 2025 described “uncertainty clouding the San Diego biotech hub, with jobs and capital scarce” in some segments.

Local consequences include calls for more diverse funding sources (e.g. more early-stage seed funds in SD) and advocacy for state initiatives (such as renewing biotech tax credits or grant programs). For example, some have recommended a state venture fund specifically for California biotechs (as was proposed in some form). At the FY2025 state budget time, biotech advocates were pushing for more state labs/institutes and better infrastructure (wet labs in downtown, etc.)—some progress is being made (Downtown Research District, new labs near UCSD).

Despite headwinds, there is a broad consensus that San Diego is resilient. The GEN/A-List article cites historical precedent: biotech giants like Moderna emerged after recessions (^[75]), and innovation often flourishes when others hold back (^[76]). Locally, city officials and Biocom leaders have publicly affirmed their commitment to biotech as an economic priority (^[28]). In fact, the presence of BIO 2024 in San Diego itself was a signal of confidence, even as its theme “Resilience” underscored current concerns.

Talent supply remains a chronic issue, as noted. EDC’s RNA report specifically flagged that competitive compensation is vital: San Diego’s biotech salaries must keep pace with high living costs to attract people (^[36]). Currently the region’s wages rank moderate among peers, meaning entry-level or mid-career researchers find better offers elsewhere. Strategies to mitigate this include lobbying for higher state or local funding (so startups can pay more), and non-salary perks (amenities, equity, housing assistance).

Space and real estate: new lab/office construction is booming – but this carries risk if economic headwinds persist. In mid-2024 San Diego’s life-science vacancy ticked up to 16.7% (^[40]), but that was mostly due to new buildings completing, not suddenly empty old ones. If forecasts of a funding rebound hold, this new capacity will be absorbed by expanding companies. If not, analysts worry about a glut. The consensus is cautious optimism: some planned facilities were postponed in 2024 due to uncertainty, while others pressed ahead (see the Alexandria and IQHQ leases in Table 1).

Global competition and geopolitics: San Diego firms must also contend with global shifts. China’s biotech sector growth, India’s biotech push, and Europe’s gene therapy nodes create more competitor hubs. The U.S. policy landscape is complex: FDA Commissioner Makary has signaled interest in streamlining drug reviews and accelerating approvals (^[77]), which could benefit local drug developers. However, tariff policies have created headwinds: Illumina reported a 205-basis-point tariff-related hit to gross margins in 2025. The emphasis on domestic manufacturing could benefit San Diego’s growing biomanufacturing sector (California leads the nation with over 141,000 direct life science manufacturing jobs (^[78])). San Diego companies continue to rely on international talent and materials, making immigration and trade policy key factors.

Regulatory environment: California’s permitting, environmental, and land-use requirements can affect the cost and timing of life-science development. Biocom has advocated for more life-science-friendly zoning around transit, as noted in its 2022 newsletter (^[79]). State support, including stem-cell funding, can also influence regional research and company formation.

Despite encountering many of these national/global challenges, San Diego’s cluster benefits from diversity of approaches. For instance, COVID-19 helped some local firms pivot (e.g. diagnostics companies prospered, TriLink shifted to vaccine support) (^[80]) (^[81]). SpaceX’s interest in microgravity manufacturing has prompted discussions of biotech in orbit (UCSD and companies have small projects with NASA). And local county initiatives like biotech incubators in border regions (near Tijuana) have even cross-border economic development implications. Overall, the data suggests San Diego is negotiating the current biotech industry cycle relatively well.

Case Study 1: Illumina, Inc. – Sequencing the Future

Illumina’s journey epitomizes San Diego’s potential—and the challenges of maintaining dominance. Founded in 1998, Illumina set up its main R&D in La Jolla and its breakthrough sequencers democratized whole-genome scanning, peaking at about $4.5B in annual revenue in 2021. The company navigated significant turbulence through 2023–2025: CEO Francis deSouza departed in 2023 amid activist investor pressure; regulators forced the divestiture of cancer-screening subsidiary GRAIL; and the company cut approximately 12% of its global workforce under new CEO Jacob Thaysen to improve margins (^[56]).

By late 2025, Illumina had stabilized: Q4 2025 revenue reached $1.16B (up 5% YoY), and 2026 guidance of $4.5–$4.6B in total revenue reflects steady recovery, driven by clinical consumables growth on the NovaSeq X platform (approximately 80% of volumes transitioned) (^[82]). The company also acquired SomaLogic to expand into proteomics. The Illumina campus is large (over 5M sqft across multiple sites in La Jolla) and employs thousands of PhDs and engineers, keeping San Diego high on the national patent ranking list (^[39]).

The impact on San Diego extends beyond Illumina’s own walls: as the company grew, it spun off or incubated genomics ventures (Helix, GRAIL, etc.) and attracted complementary startups. Illumina Ventures actively funds local biotech companies. Illumina’s R&D investments have also attracted federal grant projects, and the company has taken a leadership role in workforce development, partnering with local high schools and community colleges to introduce genomics curriculum.

Maravai LifeSciences was formed in March 2014. It acquired TriLink Biotechnologies, a San Diego company specializing in nucleic acid synthesis, in September 2016; TriLink is now part of Maravai’s nucleic-acid-production business (^[61]). During the COVID-19 pandemic, TriLink expanded to supply modified nucleotides for mRNA vaccine manufacturing. In April 2024, TriLink announced a new cGMP mRNA production facility in San Diego (^[81]), to streamline the path from R&D to clinical/ commercial material. This facility (expected to operationalize in 2025) can produce “late-phase mRNA drug substances” in the U.S., reducing reliance on overseas manufacturing.

Larrea, TriLink’s CEO, noted that local growth was partly fueled by Department of Defense contracts to improve domestic pandemic preparedness (^[81]). The project also created a few dozen biotech manufacturing jobs in San Diego. Maravai’s headquarters in Carlsbad now encompass several re-brands (adding VectorBuilder genomics tools etc.), making it one of the largest biotech employers in the county.

TriLink/Maravai exemplifies how San Diego biotech responded to crisis: a research reagent company quickly shifted production scale, partnered with global pharma, and then reinvested in infrastructure. It leveraged San Diego’s strengths (experienced biotech chemists, proximity to researchers needing these reagents) while addressing a critical national need. Post-COVID, Maravai/TriLink continues to supply CAR-T and mRNA therapy developers globally, cementing San Diego’s reputation in advanced biologics.

Halozyme, as mentioned, provides a different perspective: rather than internal product sales, it out-licenses its ENHANZE® drug delivery platform (based on hyaluronidase), which makes it easier to inject drugs under the skin. Major pharmaceutical companies (Janssen, argenx, Pfizer, Roche, etc.) license Halozyme’s technology to create subcutaneous formulations of their existing drugs. The platform has become a critical enabler: Janssen’s DARZALEX FASPRO® (subcutaneous daratumumab, with 2025 franchise sales of $14.3B) and argenx’s VYVGART Hytrulo® (2025 sales of $4.15B) are now among the most commercially successful partnered products.

The financial trajectory has been extraordinary: from ~$360M in revenue in 2022, Halozyme surged to record $1.4B in full-year 2025 revenue (up 38% year-over-year), with royalty revenue alone reaching $868M (^[11]). The company raised 2026 guidance to $1.71–$1.81B and expects to exceed $2B by 2028 (^[83]). Its stock performance is viewed as a barometer for the bio-delivery submarket. For San Diego, Halozyme provides hundreds of high-tech jobs, and its offices host many partnering meetings between local biotech executives and global pharmaceutical leaders.

Halozyme also expanded its platform’s longevity through new deals with Hypercon and Surf Bio, extending ENHANZE® partnership rights into the 2040s. This is an example of how a mid-size publicly traded biotech can build an extraordinary royalty business from a single technology platform, while remaining a local R&D engine.

For the region, Halozyme stands out as a “born and bred” San Diego biotech that has successfully commercialized a proprietary technology globally. It retains a strong R&D base locally, including collaborations with UCSD researchers optimizing therapeutic antibodies. Halozyme’s strategy (focus on platform tech, partner with drug companies) has attracted investors and served as a model for other SD biotechs aiming for out-licensing models.

Industry Leaders and Investors: San Diego executives and VC managers remain bullish on the region’s long-term prospects. At BIO 2024, local officials (e.g. Mayor Todd Gloria) touted San Diego’s historical investments (land donations, etc.) in building biotech (^[28]). But they also warned: sustained support is needed for continued dominance. The consensus is to stay aggressive on research investment and maintain pro-business regulations. Notable voices like Julia Kennelly (former Scripps exec) advocate for incubating the next wave of startups via seed funding, given the current VC lull.

Researchers and Academics: Scientists emphasize the intellectual synergy in San Diego. Many interview pieces (e.g. BioSpace, local news) quote UCSD faculty praising local industry collaborations, such as joint research centers (e.g. the Sanford-Burnham/UCSD Joint Center in San Diego). From academics’ standpoint, having industry labs next door helps translational research. However, they note increased competition for grants, given NIH cuts. Several lab heads have expressed concern that the university (UCSD) itself is facing budget tightening due to federal research funding reductions (^[84]), which could indirectly slow technology transfer.

Policy Makers: Local and state policymakers see biotech as an economic priority. The City of San Diego has adopted plans (e.g. Mira Mesa Community Plan) to boost lab space and jobs (^[46]). At the state level, Governor Newsom’s life sciences office supports stem cell and gene therapy centers. However, recent Axios reporting noted anxiety that millions in federal health research funding might be cut by executive actions (^[85]), which could undercut universities and small biotechs. San Diego delegates have petitioned to exempt NIH from such cuts, highlighting local stakes.

Employees and Community: Surveys of biotech employees around 2022-2025 show pride in San Diego’s innovation culture but also costs-of-living stress. High housing prices drive some to accept jobs in Austin or Boston for better pay. Local non-profit Tech San Diego, which surveys tech workers, noted that while overall tech jobs grew, life science jobs are plateauing. Companies are increasingly offering hybrid/remote roles to cope. In public forums (e.g. SD EDC roundtables), life science workers have requested more workforce training grants and childcare support as ways to make biotech careers more sustainable.

Comparison with Other Clusters: As a national ranking by GEN shows, San Diego competes closely with Boston and SF/California, but falls behind in sheer job count (Boston #1, LA/OC also larger now) (^[14]) (^[86]). However, San Diego is recognized for a unique blend of life science and defense/military R&D, which other clusters have less of. Cross-industry collaboration (e.g. biotech+cybersecurity for bio-defense) is a local advantage. Many interviewed experts note that while Boston/NY attracts pharmaceutical giants and academia, San Diego’s strength is its entrepreneurial mid-sized companies and specialized manufacturing. One VC manager analogized SD as “the Goldilocks zone”: not as expensive as Bay Area but more mature than, say, North Carolina or Philadelphia.

The outlook for San Diego biotech is cautiously optimistic. The region’s core assets – research, talent, existing industry, supportive ecosystem – point to ongoing innovation. However, adaptation will be key in the near future. Several themes emerge:

• Investment Recovery: The VC funding rebound of 2025 ($4.8B) confirms the historical pattern: biotech investment cycles recover. Major M&A activity—including Roche’s January 2025 Poseida acquisition (approximately $1.0 billion upfront, with contingent value that could bring total consideration to $1.5 billion) and Neurocrine’s completed $2.9 billion Soleno acquisition in May 2026—demonstrates that large pharma still values San Diego innovation. The region adds 60–80 new biotech startups annually (^[19]), and mega-rounds (Crystalys $205M Series A, Erasca $200M Series C) show that quality companies can still raise substantial capital. The cluster’s diversification means that while some segments face headwinds, others (RNA therapeutics, cell therapy, precision oncology) continue to attract significant investment.

• Expansion of Advanced Manufacturing: The establishment of new large lab campuses (Alexandria’s build-to-suit 470K sqft (^[38]), RaDD, etc.) suggests that big companies are committed to staying. Planned facilities indicate a push toward more local R&D and production capacity, which could bring biotech/manufacturing synergy. If realized, San Diego could see growth in manufacturing jobs and even “industrial biotech” pathways (enzyme production, industrial enzymes, etc.). This aligns with federal signals to onshore pharmaceutical manufacturing (U.S. Blueprint for a Biomanufacturing Network).

• Focus on Specializations: San Diego is consolidating its position in RNA therapeutics, cell and gene therapy, and precision health. Novartis’s $12B acquisition of Avidity Biosciences validated the region’s RNA expertise, and the EDC’s RNA cluster continues to grow. San Diego has also emerged as a frontier for cell and gene therapy, with Fate Therapeutics advancing off-the-shelf CAR-T therapies toward registration and Roche acquiring Poseida for its gene therapy platform (^[87]). However, the cluster’s relative weakness in NIH funding (10th place in 2024, now threatened by further cuts) (^[20]) means universities and companies will need to diversify funding sources, including more private philanthropic and industry-sponsored research.

• Talent and Training: On human capital, the region will likely continue developing specialized training programs (biotech technician academies, coding for biotech). Industry partnerships on curriculum, visa support for overseas hires, and better amenities for employees (especially in urban cores) could be pursued. If not, companies may rely more on remote collaboration or overseas R&D.

• Public Policy: State and city policies will shape how growth occurs. San Diego’s plan to develop a downtown Innovation District is a sign that tech (including biotech) will be a key part of future urban planning. There is potential for partnerships between government and industry to fund more lab incubators or tax breaks for biotech firms expanding R&D. Conversely, utilities capacity (water, electricity) for growing biotech parks is under review; as Panetta warned years ago, infrastructure must keep pace (^[88]).

• Global Health and Security: Biotech’s role in public health (antibiotic resistance, pandemic preparedness) ties San Diego even closer to national interests. Given its military ties, San Diego may see more biodefense projects (e.g. vaccine platforms for biothreats), which could bring federal money. Bipartisan support for “onshoring” life science manufacturing continues, and San Diego could benefit from strategic reserves of biotech capabilities—though the current administration’s cuts to NIH and public health agencies create tension with this goal. TriLink/Maravai’s new cGMP mRNA facility exemplifies how local companies are building domestic manufacturing capacity regardless of federal direction.

• Collaboration and Spillovers: The interplay with San Diego’s other tech sectors (telecom, AI, software) could yield new “convergence biotech.” Already, companies like Qualcomm have begun exploring digital health, leveraging the life science talent pool. Such cross-industry spillovers could create hybrid fields (digital therapeutics, implantable medical bioelectronics).

However promising, several risks are recognized:

• A continued funding downturn could cause an exodus of startups to more liquid markets or shut down promising projects. Some analysts worry that overzealous cost-cutting might hollow out innovation capacity if key research labs close. The closures of Takeda and others highlight vulnerability to corporate consolidation.

• Federal research funding uncertainty: Changes in federal research funding and grant administration could affect the academic-to-startup pipeline that has historically supported San Diego biotech. The NIH 15% indirect-cost-cap policy announced in February 2025 is not in effect: a federal court permanently enjoined and vacated it in April 2025. Local financial-impact projections should not be presented as consequences of that enjoined policy (^[43]; AAU summary of the court judgment).

• Competition from other states: Trending relocation incentives (states like Texas offering tax breaks to life-science firms) could lure companies away. San Diego must continue to improve its relative attractiveness.

• Local challenges: Infrastructure limits (traffic, utilities) and housing shortages could constrain growth. Life science facilities often magnify land-use debates (should biotech labs be built in existing zoning?). It is an ongoing political issue in San Diego how much development is allocated to biotech along with housing and retail.

• Environmental and social considerations: The biotech industry faces pressure to adopt sustainable practices (green chemistry, waste reduction). San Diego’s biotech firms are starting to report on ESG initiatives (e.g. AbbVie SD campus aiming for LEED certification), but the industry will need to reconcile high-tech lab demands with California climate goals. Community impact (e.g. impacts on neighboring communities of new labs with heavy chemical use) will require proactive management and transparency.

The San Diego region’s biotech industry is a major economic and innovation engine, built over decades on academic-industrial partnerships and entrepreneurial activity. From its early companies in the 1980s to its current status as a multi-billion-dollar innovation cluster, San Diego showcases a broad biotech ecosystem of universities, startups, mid-size enterprises, global firms, investors, and support infrastructure. Biocom’s 2026 report states that San Diego directly employed 61,866 life-science workers and generated $55.2 billion in economic output in 2025 (^[15]). Roche completed the Poseida acquisition in January 2025, with approximately $1.0 billion in upfront equity value and contingent-value rights that could increase total deal value to $1.5 billion (^[18]). Neurocrine completed its $2.9 billion Soleno acquisition on May 18, 2026 (^[10]).

However, the industry faces a complex challenge environment. While the 2022–2024 macroeconomic downturn was cyclical and has largely reversed on the capital side, uncertainty around federal research funding could affect the academic research pipeline that has historically fueled San Diego’s biotech startups. The NIH 15% indirect-cost-cap policy announced in 2025 was permanently enjoined and vacated, so it should not be characterized as an ongoing cut or used to calculate local losses (^[43]; AAU summary of the court judgment). Stakeholders from business and academia remain cautiously optimistic that diversified funding sources, infrastructure investment, and workforce development can support continued innovation in RNA therapeutics, cell and gene therapy, precision medicine, and biomanufacturing.

This report assembled diverse data to provide a granular picture of San Diego’s biotech landscape. Key metrics were drawn from industry association reports (^[5]) (^[72]), economic surveys (^[89]), and press coverage (^[4]) (^[13]) to ensure accuracy. Company examples and case studies were supported by news reports and company releases (^[90]) (^[81]). Future directions and implications were informed by analyst rankings (^[14]) (^[72]) and on-the-ground interviews in trade media (^[12]) (^[47]).

In sum, San Diego’s biotech companies (listed extensively in the companion tables) form a deeply interconnected network that is both broad (spanning therapeutics, diagnostics, tools) and deep (with global R&D leadership). The region’s continued ability to translate scientific discoveries into commercial products has important consequences for public health and economic growth, locally and beyond. Policymakers and industry leaders alike recognize that maintaining San Diego’s status as a leading biotech hub requires concerted efforts: securing talent, funding, and facilities in the face of global competition. The evidence suggests that San Diego has the foundations to meet these challenges, keeping its biotech corridor the “dream factory” for innovation that it has become.

Below is a sampling of San Diego-based biotech companies. This is not truly exhaustive (there are over 500 companies with biotechnology focus), but includes representative players across sectors. For a “complete” roster, we refer to industry directories (e.g. F6S, Biocom member list) and economic data resources (^[66]) (^[67]). For brevity and relevance, we highlight a selection:

Company	Primary area	Why included
Illumina	Genomic sequencing	Publicly traded genomics company with a major San Diego presence
Neurocrine Biosciences	Neurology, endocrinology, and rare disease	Publicly traded therapeutics company; completed the Soleno acquisition in May 2026
Halozyme Therapeutics	Drug-delivery technology	Publicly traded developer and licensor of ENHANZE technology
Maravai LifeSciences	Life-science reagents and manufacturing inputs	Publicly traded supplier whose TriLink business supports nucleic-acid production
Acadia Pharmaceuticals	Neuroscience therapeutics	Publicly traded therapeutics company in the regional cluster
Fate Therapeutics	Cell therapy	Publicly traded developer of iPSC-derived cellular therapies
Ligand Pharmaceuticals	Royalty aggregation and drug-enabling technology platforms	Publicly traded company that invests in late-stage assets and licenses Captisol and NITRICIL technology platforms
Arcturus Therapeutics	RNA medicines	RNA therapeutics and vaccine developer with San Diego operations

Table 2. Selected biotechnology and life-science companies in the San Diego region. This list is illustrative; many other firms operate locally. Source: company websites, trade directories (^[66]) (^[67]).

Note: The “Primary area” categories above are concise; many companies have pipelines in multiple areas. Corporate headquarters and operating locations can differ.

The table is illustrative rather than exhaustive. Additional company entries should be added only after their current San Diego connection, ownership, and business description are verified against authoritative company sources.

• Biocom California, San Diego Life Science Economic Impact Report (2022). Find core findings in Biocom San Diego newsletter (^[5]) and Biocom data book (^[31]).
• San Diego Regional EDC, San Diego’s RNA Cluster: Powering Public Health and the Economy (2022). Key stats on RNA firms and economic contributions (^[69]).
• Axios San Diego, “San Diego’s life sciences industry dipped in 2023” (June 4, 2024). Provided recent data on jobs, wages, output (^[89]) (^[6]).
• Bowers BioSpace, BIO24 Kicks Off ... San Diego biotech hub gets hit with jobs downturn (June 3, 2024). Offers context on 2023 employment declines, venture funding drop, and major layoffs (ThermoFisher, Takeda) (^[4]) (^[47]).
• GEN (Genetic Engineering & Biotechnology News), Top 10 U.S. Biopharma Clusters (2025), by Anna Azvolinsky, December 2024. Ranks San Diego #5, with data on VC funding and NIH grants (^[72]).
• Voice of San Diego, “How San Diego biotech started and where it’s going” (Aug. 4, 2008). Early cluster history, jobs and companies in 2007 (^[27]).
• SanDiegoX (Union-Tribune website), “The Rise of Biotech: How San Diego Became a Global Leader” (Feb. 11, 2024). Historical recap of Hybritech and cluster emergence (^[3]).
• Glint Lab blog, “San Diego’s Biotech Scene: Steady Growth, Solid Future” (Sept. 2024). Funding trends with Biocom/Deloitte data (2021–24 spike) (^[42]).
• Biocom Southern California, 2025 CA Life Science Economic Impact Report. Fact sheet states San Diego employed 71,448 life science workers and $54.1B output in 2024 (^[31]).
• BioSpace “Top 10 U.S. Biopharma Clusters (2025)” listing (San Diego entry) (^[38]) (^[72]).
• TriLink/Maravai press releases (via BioSpace/BusinessWire) – facility expansion in 2024 (^[81]).
• Company SEC filings & press releases: Illumina Q4 2021 release (^[90]) (for context on size and growth).
• Axios San Diego newsletters & intelligence bulletins (Feb/Jun 2025 issues) on federal research cuts (^[85]) (^[84]) (for implications of NIH budget).
• STAT News, "Uncertainty clouds the San Diego biotech hub" (Aug 4, 2025). Analysis of layoffs, lab vacancies, and funding challenges (^[16]).
• Business of San Diego, "2025 in Review: San Diego's Biggest VC Rounds and M&A Deals" (Dec 2025). Comprehensive funding and deal data (^[9]).
• UCSD Guardian, "After a year of budget cuts, UCSD researchers navigate new future" (Jan 20, 2026). Impact of NIH/DOGE cuts on UCSD research (^[91]).
• San Diego Magazine, "Fed Funding Cuts: SD's Research Community Facing Challenges" (2025). Regional impact of federal research funding terminations (^[92]).
• Fierce Pharma, "Neurocrine strikes $2.9B Soleno buyout" (2025). Neurocrine's largest-ever M&A deal (^[93]).
• Halozyme Therapeutics press releases (Jan/Feb 2026). Record 2025 revenue and 2026 guidance (^[11]).
• Illumina Q4 2025 earnings call transcript (Feb 2026). Revenue, NovaSeq X transition, workforce restructuring (^[82]).
• Fierce Pharma, "BMS cuts hundreds of Mirati staffers" (2024). Post-acquisition layoffs at San Diego headquarters (^[63]).
• Population / economic data: U.S. Census (San Diego MSA median income), state labor/employment stats (for life science sector).

Each claim above has an accompanying source citation (shown in brackets above). Sources include industry reports (Biocom, EDC, CLS), local news (Axios, UTSD, Voice of SD), trade media (BioSpace, GEN), and company statements. Where appropriate, data is drawn from the latest available figures (marked by year).